Bitterman Robert J's Form 4 filing
Phio Pharmaceuticals Corp. (PHIO) · filed Jun 10, 2024
- Accession no.
- 0001683168-24-004089
- Filed
- Jun 10, 2024
- Trade date
- Jun 6, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $750. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bitterman Robert JCIK 0001304395 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 6, 2024 | Common stock, $0.0001 par value | PPurchaseAcquired | +1,000 | $0.75 | +$750 | 19,990 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.